Shares of Echo IQ Limited slumped 7.6% to A$1.40 on August 31, marking the market's verdict on annual results that showed a company burning cash far faster than it is generating income, raising pointed questions about how long the balance sheet can sustain its ambitious medical-AI pivot. Echo IQ Posts A$18.6 Million Loss on Just A$91,646 in Revenue — Is A$110 Million in Fresh Cash Enough to Bridge the Gap to Profitability?

Shares slid 7.6% to A$1.40 after Echo IQ's FY26 annual results confirmed that its pivot into AI-powered heart diagnostics is costing far more than it earns, forcing investors to weigh a promising technology pipeline against a financial statement that shows virtually no revenue.

• A$18.6 Million Lost on Less Than A$92,000 in Sales

Echo IQ released its financial statements for the year ended 30 June 2026. The after-tax loss widened 40% to A$18.6 million, while ordinary-activity revenue fell 8.9% to just A$91,646. That means the company spent roughly $203 for every $1 it earned — a ratio that underscores how early-stage its commercial efforts remain. The company is currently unprofitable and not forecast to become profitable over the next two years.

• Cash Was Running Low Before a Massive Rescue Raise

Cash at 30 June 2026 was just A$8.7 million, down from A$11.14 million at 31 March, but improved post-period with the A$110 million placement and Pro Medicus agreement.

At quarter-end the company estimated only 3.2 quarters of funding remained. The July placement — priced at A$1.45 per share — bought crucial time, but today's A$1.40 price sits below that placement price, meaning new investors are already underwater.

• Big-Name Partners Haven't Yet Translated Into Revenue

Echo IQ executed a binding agreement with Pro Medicus for up to A$20 million and a US commercial partnership.

It has FDA clearance for its aortic stenosis software, while its heart failure product is under FDA review.

Operationally, it processed 9,220 echocardiograms in Q1 calendar 2026, representing 131% quarter-on-quarter growth. But those scans have yet to generate meaningful subscription income, leaving investors reliant on future conversion.

• The Stock's Surge Has Outrun the Fundamentals — For Now

The stock price has risen 440% in the past 52 weeks , largely on the FDA milestone and Pro Medicus deal. With 660.86 million shares outstanding and a price of A$1.40, the implied market capitalisation is roughly A$925 million — an enormous valuation for a company with sub-A$100,000 in annual revenue. The most recent analyst rating is a Buy with an A$1.85 target , but that requires revenue to materialise. The investment case now hinges on FDA heart-failure clearance, revenue acceleration in late 2026, and reimbursement pathways firming up — miss on any one and the raise gets consumed faster than the ramp delivers.